The complete exclusion of plaintiffs’ expert testimony on damages and loss causation has led a federal appeals court to reinstate a securities class action alleging Pfizer made misrepresentations concealing cardiovascular risks associated with two of its drugs.
Reversing a lower court, the U.S. Court of Appeals for the Second Circuit revived a 10-year-old case alleging Pfizer’s stock price dropped because of statements it made about the drugs Celebrex and Bextra.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
